0000000000723925

AUTHOR

Averna Maurizio

showing 3 related works from this author

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

2015

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 yea…

RegistrieMaleCross-sectional studyMyocardial InfarctionLongitudinal StudieLeft ventricular hypertrophyCohort Studiesnon-valvular atrial fibrillationAtrial Fibrillation80 and overPrevalenceechocardiographyMyocardial infarctionLongitudinal StudiesProspective StudiesRegistriesProspective cohort studyUltrasonographyAged 80 and overeducation.field_of_studyMedicine (all)Atrial fibrillationDiabetes MellituMiddle AgedLeft Ventricularleft ventricular hypertrophyItalyHypertensionCardiologyAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)Hypertrophy Left VentricularFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelPopulationConcentric hypertrophySocio-culturalenon-valvular atrial fibrillation left ventricular hypertrophy echocardiography cardiovascular diseasesPeripheral Arterial DiseaseAge DistributionInternal medicinemedicineDiabetes MellitusHumansAnkle Brachial Indexcardiovascular diseaseseducationAgedCross-Sectional Studiebusiness.industryAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular MedicineOdds ratioHypertrophymedicine.diseasecardiovascular diseasesProspective StudieCross-Sectional StudiesLogistic ModelsCohort StudiebusinessAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries
researchProduct

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Melli…

2010

AIMS: This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. METHODS: Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients …

SulfonamidesSimvastatinSettore MED/09 - Medicina InternaAnticholesteremic AgentsHypercholesterolemiaDrug ResistanceCholesterol LDLEzetimibeLipidsFluorobenzenesC-Reactive ProteinCholesterolPyrimidinesDiabetes Mellitus Type 2Double-Blind MethodOdds RatioDiabetes MellitusAzetidinesHumansDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumApolipoproteins B
researchProduct

A novel putative interactor for the low density lipoprotein receptor cytoplasmic domain

2011

Familial hypercholesterolemia (FH) is a genetic disease mainly caused by mutations in the low density lipoprotein receptor (LDLLDLLDL-R) gene. However, FH-like phenotypes may also arise from mutations occurring in other genes, the products of which normally interact with the LDLLDLLDL receptor. Although several FH-associated proteins have been discovered, many FH-like phenotypes cannot be linked to mutations in already characterized genes, suggesting the existence of other genes still to be identified, the mutations of which may be directly linked to the FH disorder. In order to identify new putative LDLLDLLDLr interactors possibly involved in its internalization and/or sorting, the cytopla…

lipoprotein receptortwo-hybrid assaySettore BIO/11 - Biologia Molecolarelow density lipoprotein receptor interactor
researchProduct